Literature DB >> 16257564

Hepatic fibrosis and cirrhosis: the (myo)fibroblastic cell subpopulations involved.

Christelle Guyot1, Sébastien Lepreux, Chantal Combe, Evelyne Doudnikoff, Paulette Bioulac-Sage, Charles Balabaud, Alexis Desmoulière.   

Abstract

Fibrosis, defined as the excessive deposition of extracellular matrix in an organ, is the main complication of chronic liver damage. Its endpoint is cirrhosis, which is responsible for significant morbidity and mortality. The accumulation of extracellular matrix observed in fibrosis and cirrhosis is due to the activation of fibroblasts, which acquire a myofibroblastic phenotype. Myofibroblasts are absent from normal liver. They are produced by the activation of precursor cells, such as hepatic stellate cells and portal fibroblasts. These fibrogenic cells are distributed differently in the hepatic lobule: the hepatic stellate cells resemble pericytes and are located along the sinusoids, in the Disse space between the endothelium and the hepatocytes, whereas the portal fibroblasts are embedded in the portal tract connective tissue around portal structures (vessels and biliary structures). Differences have been reported between these two fibrogenic cell populations, in the mechanisms leading to myofibroblastic differentiation, activation and "deactivation", but confirmation is required. Second-layer cells surrounding centrolobular veins, fibroblasts present in the Glisson capsule surrounding the liver, and vascular smooth muscle cells may also express a myofibroblastic phenotype and may be involved in fibrogenesis. It is now widely accepted that the various types of lesion (e.g., lesions caused by alcohol abuse and viral hepatitis) leading to liver fibrosis involve specific fibrogenic cell subpopulations. The biological and biochemical characterisation of these cells is thus essential if we are to understand the mechanisms underlying the progressive development of excessive scarring in the liver. These cells also differ in proliferative and apoptotic capacity, at least in vitro. All this information is required for the development of treatments specifically and efficiently targeting the cells responsible for the development of fibrosis/cirrhosis.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16257564     DOI: 10.1016/j.biocel.2005.08.021

Source DB:  PubMed          Journal:  Int J Biochem Cell Biol        ISSN: 1357-2725            Impact factor:   5.085


  85 in total

Review 1.  Recent developments in myofibroblast biology: paradigms for connective tissue remodeling.

Authors:  Boris Hinz; Sem H Phan; Victor J Thannickal; Marco Prunotto; Alexis Desmoulière; John Varga; Olivier De Wever; Marc Mareel; Giulio Gabbiani
Journal:  Am J Pathol       Date:  2012-03-02       Impact factor: 4.307

2.  Hepatocyte apoptotic bodies encasing nonstructural HCV proteins amplify hepatic stellate cell activation: implications for chronic hepatitis C.

Authors:  R K Gieseler; G Marquitan; M Schlattjan; J-P Sowa; L P Bechmann; J Timm; M Roggendorf; G Gerken; S L Friedman; A Canbay
Journal:  J Viral Hepat       Date:  2010-08-15       Impact factor: 3.728

3.  Schistosoma japonicum protein SjP40 inhibits TGF-β1-induced activation of hepatic stellate cells.

Authors:  Xiaolei Sun; Lingbo Zhang; Jianxin Wang; Jinling Chen; Dandan Zhu; Pei Shen; Xue He; Jing Pan; Wenxia Peng; Yinong Duan
Journal:  Parasitol Res       Date:  2015-08-14       Impact factor: 2.289

4.  Contribution of Myofibroblasts of Different Origins to Liver Fibrosis.

Authors:  Michel Fausther; Elise G Lavoie; Jonathan A Dranoff
Journal:  Curr Pathobiol Rep       Date:  2013-09

5.  Specific activation of the different fibrogenic cells in rat cultured liver slices mimicking in vivo situations.

Authors:  Christelle Guyot; Chantal Combe; Haude Clouzeau-Girard; Valérie Moronvalle-Halley; Alexis Desmoulière
Journal:  Virchows Arch       Date:  2007-03-13       Impact factor: 4.064

Review 6.  Anti-fibrogenic strategies and the regression of fibrosis.

Authors:  Tatiana Kisseleva; David A Brenner
Journal:  Best Pract Res Clin Gastroenterol       Date:  2011-04       Impact factor: 3.043

7.  Hyperoxia accelerates progression of hepatic fibrosis by up-regulation of transforming growth factor-β expression.

Authors:  Sang Hwa Lee; Sung-Im Do; Hyun-Soo Kim
Journal:  World J Gastroenterol       Date:  2014-03-21       Impact factor: 5.742

8.  Tissue stiffness, latent TGF-beta1 activation, and mechanical signal transduction: implications for the pathogenesis and treatment of fibrosis.

Authors:  Boris Hinz
Journal:  Curr Rheumatol Rep       Date:  2009-04       Impact factor: 4.592

Review 9.  Hepatic regeneration and the epithelial to mesenchymal transition.

Authors:  Zeng-Fu Xue; Xiu-Min Wu; Ming Liu
Journal:  World J Gastroenterol       Date:  2013-03-07       Impact factor: 5.742

Review 10.  Cellular sources of extracellular matrix in hepatic fibrosis.

Authors:  Rebecca G Wells
Journal:  Clin Liver Dis       Date:  2008-11       Impact factor: 6.126

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.